Published on 13 Jun 2023 on Simply Wall St. via Yahoo Finance
Exagen Inc.'s (NASDAQ:XGN) Low P/S No Reason For Excitement
With a price-to-sales (or "P/S") ratio of 1.2x Exagen Inc. (NASDAQ:XGN) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the United States have P/S ratios greater than 12.7x and even P/S higher than 65x are not unusual. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.
View our latest analysis for Exagen
